Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

75

LONDON–(BUSINESS WIRE)–GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved…

 

 

http://www.businesswire.com/news/home/20190606005859/en/Nucala-mepolizumab-Gains-FDA-Approval-New-Self-Administration